Artificial intelligence in healthcare is one of the clearest ways technology meets real world need, especially as higher energy prices, geopolitical tension, and sticky inflation keep pressure on costs and productivity. While many sectors face softer activity and rising input prices, AI tools that support better diagnostics, smoother hospital operations, and faster drug discovery speak directly to efficiency and outcomes. This screener focuses on companies applying AI to these problems, helping you focus on businesses tied to long term shifts in how care is delivered. Below, you will see 3 stocks from the Transformative AI Healthcare Stocks list.

Medtronic (MDT)

Overview: Medtronic is a large medical device company that supplies surgeons and clinicians with products such as heart pacemakers and defibrillators, spinal and brain implants, surgical tools and robotics, and insulin pumps and glucose monitors for diabetes care across the United States and international markets.

Operations: Medtronic generates most of its revenue from Cardiovascular (US$13.5b), Neuroscience (US$10.2b), Medical Surgical (US$8.6b), and Diabetes (US$3.0b), with the United States contributing US$17.8b and the rest of the world US$17.6b.

Market Cap: US$110.8b

Investors looking at AI in healthcare may find Medtronic interesting because its core cardiac, neurosurgical, and surgical device franchises are increasingly tied to software, data, and robotics, from AI powered surgical video platforms to the Stealth AXiS navigation system and ALERT trial work in heart valve care. The company backs this with sizeable R&D, a long dividend record at a 3.29% yield, and earnings that analysts expect to grow faster than its recent 5 year trend. At the same time, competition in diabetes tech, product recall history, and reliance on external borrowing keep risk on the table. The full picture of how these strengths and pressures fit together is where the real opportunity could lie for you.

Medtronic’s AI linked devices, robotics, and software could tell a different story than its headline dividend yield suggests. See how analyst expectations line up in the analyst forecasts for Medtronic and what might be hiding beneath them.

Insmed (INSM)

Overview: Insmed focuses on therapies for serious and rare diseases, with an approved lung infection treatment, ARIKAYCE, and a deep pipeline targeting bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and other hard to treat conditions.

Operations: Insmed generates about US$606.4m in revenue from therapies for rare disease patients, with roughly US$453.0m from the United States and US$153.5m from international markets.

Market Cap: US$35.2b

Insmed stands out in AI focused healthcare because its core respiratory and rare disease portfolio is already commercial, yet still closely tied to upcoming data and approvals that could reshape the business, from brensocatib in bronchiectasis to TPIP in pulmonary hypertension and potential ARIKAYCE label expansion. Analysts highlight revenue and earnings growth potential, but this depends on approvals, payer support, and successful market access, while the company remains loss making and reliant on external funding and fresh equity. For investors willing to take on that risk, the combination of multiple late stage programs, expanding international reach, and analyst targets presents a story that is more layered than a simple high growth biotech label suggests.

Insmed’s late stage pipeline and rare disease focus may be masking a broader story about how all those moving parts fit together. See how the analysis report for Insmed explains the potential upside along with the risks that could change the outlook.

Stryker (SYK)

Overview: Stryker is a global medical technology company that supplies hospitals and clinicians with surgical equipment, neurotechnology devices, AI assisted virtual care and communication platforms, and orthopaedic implants for joint replacement and trauma care.

Operations: Stryker generates about US$9.5b from Orthopaedics and US$15.6b from MedSurg and Neurotechnology, with most revenue coming from the United States and additional contributions from Europe, the Middle East, Africa, Asia Pacific, and other international markets.

Market Cap: US$127.2b

Stryker sits at the intersection of hardware and software in healthcare, combining orthopaedic implants and smart robotics like Mako with AI assisted hospital and virtual care platforms. It carries debt on its balance sheet, and recent cyberattacks highlight how exposed connected hospital suppliers can be. Earnings, return on equity forecasts and ongoing investment in connected operating rooms, stroke care and digital SmartHospital services indicate a business that is still evolving. For investors interested in AI health tools backed by an established, profitable medical device franchise, the key consideration is how that mix of growth, risk and valuation fits together beyond the headlines.

Mako robotics and SmartHospital services hint at an AI engine that could be masking where the real value sits. See how the analyst forecasts for Stryker reframes Stryker’s future or exposes the pressure point investors rarely discuss.

The three stocks covered here are just a starting sample, with the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfacing 34 more companies where AI is reshaping diagnostics, care delivery, and cost efficiency with equally compelling stories. Use Simply Wall St to identify, filter, and analyze the specific catalysts and narratives that matter to you so you can focus on your highest conviction AI healthcare ideas.

Take Control of Your Investment Journey

If Stryker or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your top picks to a Watchlist to monitor the share price against the fair value for the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About Alternative Stock Paths?

Fresh ideas can move from quiet to breakout quickly, and once momentum is clear the best entry points may be gone. Review these under the radar lists and consider whether any fit your approach.

• Spot companies quietly building strength before momentum headlines start by reviewing the carefully filtered list of solid balance sheet and fundamentals (40 results).
• Explore potential income plus resilience by checking out a curated group of high yield opportunities in the 13 dividend fortresses.
• Stay informed about developments in computing by scanning the hand picked names inside the 23 quantum computing stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.